Literature DB >> 18655875

Regulation of vasopressin release by co-released neurotransmitters: mechanisms of purinergic and adrenergic synergism.

Celia D Sladek1, Zhilin Song.   

Abstract

Arginine vasopressin (AVP) neurons of the hypothalamo-neurohypophseal system (HNS) are innervated by numerous afferent pathways carrying information about two physiologically important parameters: blood volume/pressure and osmolality. These pathways use a variety of neurotransmitters/neuropeptides. In order to understand normal and pathological regulation of VP secretion, the mechanisms underlying integration of these complex afferent signals by the AVP neurons must be understood. The importance of neurotransmitter interactions in determining hormone release is highlighted by the finding that simultaneous exposure to adenosine triphosphate (ATP, a neurotransmitter acting on purinergic receptors) and phenylephrine (PE; to mimic norepinephrine activation of alpha1-adrenergic receptors) results in potentiation of AVP release that is characterized by an increase in the peak response and conversion of a transient response to a response that is sustained for hours. Evaluation of the mechanisms responsible for this response indicated that (1) activation of P2X purinergic receptors (P2X-R) is required, (2) protein kinase C (PKC) activation is required, (3) the sustained component requires new gene transcription, (4) the synergism does not involve presynaptic mechanisms nor does it occur directly in the neural lobe and (5) live-cell Ca(++) imaging techniques demonstrated a sustained increase in [Ca(++)](i) and that ATP activates P2Y-Rs as well as P2X-Rs in supraoptic neurons. Since the subtypes of P2X-Rs differ in their rate of desensitization, identification of the subtype of P2X-Rs participating in the initial and sustained responses to ATP+PE may elucidate mechanisms underlying the abrupt and transient responses to orthostatic hypotension versus sustained responses to chronic hypovolemia or vasodilation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18655875     DOI: 10.1016/S0079-6123(08)00409-3

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  8 in total

1.  Knocking out P2X receptors reduces transmitter secretion in taste buds.

Authors:  Yijen A Huang; Leslie M Stone; Elizabeth Pereira; Ruibiao Yang; John C Kinnamon; Gennady Dvoryanchikov; Nirupa Chaudhari; Thomas E Finger; Sue C Kinnamon; Stephen D Roper
Journal:  J Neurosci       Date:  2011-09-21       Impact factor: 6.167

Review 2.  Subtypes of functional alpha1-adrenoceptor.

Authors:  James R Docherty
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

3.  Interaction of alpha1D-adrenergic and P2X(7) receptors in the rat lacrimal gland and the effect on intracellular [Ca2+] and protein secretion.

Authors:  Darlene A Dartt; Robin R Hodges
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

Review 4.  Purinergic signaling pathways in endocrine system.

Authors:  Ivana Bjelobaba; Marija M Janjic; Stanko S Stojilkovic
Journal:  Auton Neurosci       Date:  2015-04-25       Impact factor: 3.145

5.  Central diabetes insipidus: a previously unreported side effect of temozolomide.

Authors:  Alexander T Faje; Lisa Nachtigall; Deborah Wexler; Karen K Miller; Anne Klibanski; Hideo Makimura
Journal:  J Clin Endocrinol Metab       Date:  2013-08-08       Impact factor: 5.958

Review 6.  Purinergic signalling in endocrine organs.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

7.  P2X7 receptors in neurohypophysial terminals: evidence for their role in arginine-vasopressin secretion.

Authors:  Adolfo E Cuadra; Edward E Custer; Elizabeth L Bosworth; José R Lemos
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

Review 8.  Bench-to-bedside review: Vasopressin in the management of septic shock.

Authors:  James A Russell
Journal:  Crit Care       Date:  2011-08-11       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.